SMA Newsroom

ResearchTreatmentsClinical trialsMay 31, 2022

Roche Community Update: FDA (U.S. Food and Drug Administration) approves a label expansion for risdiplam

Today, the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under two months old with spinal muscular atrophy (SMA). This means that risdiplam is now approved in the US to treat SMA in children and adults of all ages. 

ResearchMar 8, 2022

Biogen develops BIIB115, a potential new treatment for SMA

In response to our request, Biogen has shared a community update to announce that they are moving ahead with an early-stage investigation into a new treatment for SMA that could potentially treat further unmet needs.